stockportfolio.pro
Stocks / ACAD vs DOCS
ACAD vs DOCS
ACADIA Pharmaceuticals Inc. and Doximity, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ACADIA Pharmaceuticals Inc. (ACAD) | Doximity, Inc. (DOCS) | |
|---|---|---|
| Market cap | $3.7B | $3.7B |
| Revenue (latest FY) | $1.07B | $644.86M |
| Net income (latest FY) | $391.00M | $196.05M |
| Revenue growth (5y CAGR) | 19.4% | 25.5% |
| Net margin | 36.5% | 30.4% |
| Return on equity | 31.9% | 20.6% |
| P/E ratio | 9.7 | 20.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ACAD — free Open DOCS — freeFrequently asked questions
Which is bigger, ACAD or DOCS?
Doximity, Inc. is larger by market capitalization — $3.7B versus $3.7B.
Which grows faster, ACAD or DOCS?
Over the last five fiscal years, Doximity, Inc. grew revenue faster — 25.5%/yr versus 19.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.